Phaseline

Targets › PDE4A

PDE4A (3',5'-cyclic-AMP phosphodiesterase 4A): drug programs, companies and trials

27 programs from 26 companies in 75 trials: 41 Phase 2, 15 Phase 3, 10 Phase 1, 9 Phase 4; Immunology, Other, Genitourinary; next expected readout Nov 2026.

Hydrolyzes the second messenger 3',5'-cyclic AMP (cAMP), which is a key regulator of many important physiological processes..; FUNCTION: [Isoform 1]: Efficiently hydrolyzes cAMP..; FUNCTION: [Isoform 2]: Efficiently hydrolyzes cAMP..; FUNCTION: [Isoform 3]: Efficiently hydrolyzes cAMP. The phosphodiesterase activity is not affected by calcium, calmodulin or cyclic GMP (cGMP) levels. Does not hydrolyze cGMP..;…. (UniProt, P27815)

Open in Phaseline: the race on PDE4A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
St Joseph University, Beirut, LebanonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Lumbar RadiculopathyDec 2026
Integrative Skin Science and ResearchRoflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 4ITCHAug 2027
VA Office of Research and DevelopmentPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Diabetic Kidney DiseaseJan 2028
Vastra Gotaland RegionDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 4Takotsubo SyndromeDec 2028
Massachusetts General HospitalTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 4PHP IaApr 2030
Cairo UniversityCrisaborole
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3VitiligoNov 2026
Al-Azhar UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Chronic Kidney DiseasesDec 2026
Ganzhou Hemay PharmaceuticalHemay005
Phosphodiesterase 4 (PDE4) inhibitor
PDE4A, PDE4B, PDE4C, PDE4DPhase 3Behçet's Disease; Moderate to Severe Ulcerative Colitis; PsoriasisDec 2026
Tanta UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3IBS - Irritable Bowel Syndrome; Rheumatoid ArthritisMay 2027
AmgenApremilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Plaque Psoriasis; Active Juvenile Psoriatic Arthritis; Behçet Disease; Behçet's Disease …Mar 2028
Arcutis BiotherapeuticsRoflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 3Atopic Dermatitis; Chronic Plaque Psoriasis; Depressive Disorder, Major; Fragile X Syndrome …Apr 2028
Merck & Co. (MSD)Ensifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 3Pulmonary Disease, Chronic ObstructiveApr 2029
University of WashingtonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Medication-related Osteonecrosis of the Jaw–
Beni-Suef Universitypentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Embryo Transfer–
Vanderbilt University Medical CenterTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2PseudohypoparathyroidismDec 2026
Mostafa BahaaPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2EpilepsyDec 2026
Yunfeng XiaDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2Restless Leg Syndrome Due to UraemiaDec 2026
Ihab Elsayed HassanPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Inflammatory Bowel DiseasesJan 2027
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEnsifentrine (MK-5884)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Pulmonary Disease, Chronic Obstructive, COPD; Non-cystic Fibrosis BronchiectasisMar 2027
Beni-Suef UniversityAminophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Acute Calculous Anuria; Pediatric Urolithiasis; Renal StonesMar 2027
University Hospital, LimogesPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Medication-related Osteonecrosis of the Jaw (MRONJ)Apr 2027
MediciNovaIbudilast (MN-166)
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3A inhibitor; Phosphodiesterase 10A inhibitor
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 2Amyotrophic Lateral SclerosisApr 2027
Stanford UniversityDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2HypophosphatemiaMay 2027
M.D. Anderson Cancer CenterPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Lymphedema; Fibrosis SyndromeMay 2029
University Health Network, TorontoPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Non-Small Cell Lung CancerNov 2031
Medical College of WisconsinTheophylline
Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor; Adenosine receptor antagonist
PDE4A, PDE4D, PDE4B, PDE4C, PDE3APhase 1Acute Kidney InjuryMay 2027

Conditions

Alcohol Use Disorder (5) Rheumatoid Arthritis (3) Behçet's Disease (2) Pseudohypoparathyroidism (2) Acute Kidney Injury (2) Head and Neck Squamous Cell Carcinoma (2) Atopic Dermatitis (2) Hidradenitis Suppurativa (HS) (2) Plaque Psoriasis (1) Active Juvenile Psoriatic Arthritis (1) Behçet Disease (1) Recurrent Aphtous Stomatitis (1)

Modalities

small molecule (27)

Companies

Beni-Suef University (2) Amgen (1) University of Washington (1) University Hospital, Limoges (1) MediciNova (1) Stanford University (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) Vastra Gotaland Region (1) VA Office of Research and Development (1) Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (1) Ganzhou Hemay Pharmaceutical (1) Ihab Elsayed Hassan (1) Vanderbilt University Medical Center (1) Cairo University (1) University of Pennsylvania (1) Al-Azhar University (1) Merck & Co. (MSD) (1) Yunfeng Xia (1) Medical College of Wisconsin (1)

Related targets

PDE3A (22) PDE5A (14) PDE4D (13) PDE4B (13) PDE4C (13) ADORA2B (11) ADORA2A (11) SLC29A1 (3) PDE6H (3) CHRNA4 (1) OPRK1 (1) OPRD1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.